Hemostasis and coagulation monitoring and management during liver transplantation

Current Opinion in Organ Transplantation

Volumn 14, Issue 3, 2009, Pages 286-290

  Dalmau, Antònia ^a   Sabaté, Antoni ^a   Aparicio, Idoia ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Antifibrinolytics; Cirrhotic coagulopathy; Liver transplantation; Procoagulants drugs; Transfusion

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIFIBRINOLYTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR 7; DESMOPRESSIN; DIURETIC AGENT; FIBRINOGEN; FRESH FROZEN PLASMA; LYSINE DERIVATIVE; PROCOAGULANT; THROMBIN; VON WILLEBRAND FACTOR; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; BLOOD VOLUME; CLINICAL TRIAL; CRYOPRECIPITATE; DRUG MECHANISM; ERYTHROCYTE TRANSFUSION; FLUID THERAPY; HEMODILUTION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERVOLEMIA; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PHLEBOTOMY; PROPHYLAXIS; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; SIDE EFFECT; THROMBIN TIME; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; THROMBOSIS; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG MONITORING; PRACTICE GUIDELINE;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD LOSS, SURGICAL; DRUG MONITORING; FIBRINOLYTIC AGENTS; FLUID THERAPY; HEMORRHAGE; HEMOSTASIS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PLATELET TRANSFUSION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; THROMBOSIS;

EID: 67651009564     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32832a6b7c     Document Type: Review

References (54)

1. Boer MT, Christensen MC, Amussen M, et al. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 2008; 106:32-44.
2. Dalmau A, Sabate A, Koo M, et al. Prophylactic use of tranexamic acid and incidence of arterial thrombosis in liver transplantation. Anesth Analg 2001; 93:514-519. (Pubitemid 32701559)
3. Massicotte L, Sassine MP, Lenis S, et al. Survival rate changes with transfusion of blood products during liver transplantation. Can J Anesth 2005; 52:148-155. (Pubitemid 40467971)
4. Dalmau A, Sabate A, Koo M, et al. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study. Liver Transpl 2004; 10:279-284. (Pubitemid 38240128)
5. Frasco PE, Poterack KA, Hentz JG, et al. A comparison of transfusion requirements between living donation and cadaveric donation liver transplantation: relationship to model of end-stage liver disease score and baseline coagulation status. Anesth Analg 2005; 101:30-37.
6. Mangus RS, Kinsella SB, Nobari MM, et al. Predictors of blood product use in orthotopic liver transplantation using the piggyback hepatectomy technique. Transplant Proc 2007; 39:3207-3213.
7. Massicotte L, Beaulieu D, Thibeault L, et al. Coagulation defects do not predict blood product requirements during liver transplantation. Transplantation 2008; 85:956-962. (Pubitemid 351543157)
8. Massicotte L, Sassine MP, Lenis S, Roy A. Transfusion predictors in liver transplant. Anesth Analg 2004; 98:1245-1251.
9. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41:553-558. (Pubitemid 40289502)
10. Kiszka-Kanowitz M, Henriksen JH, Moller S, et al. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J Hepatol 2001; 35:605-612. (Pubitemid 33078270)
11. Massicotte L, Lenis S, Thibeault L, et al. Effect of low central venous pressure and phlebotomy on blood product transfusion requirements during liver transplantations. Liver Transpl 2006; 12:117-123; 17. (Pubitemid 44194602)
12. Schroeder RA, Collins BH, Tuttle-Newhall E, et al. Intraoperative fluid management during orthotopic liver transplantation. J Cardiothorac Vasc Anesth 2004; 18:438-441.
13. Koo M, Sabate A, Ramos E, et al. Factors related to renal dysfunction after liver transplantation in patients with normal preoperative function. Rev Esp Anestesiol Reanim 2006; 53:538-544.
14. Jovine E, Mazziotti A, Grazi GL, et al. Piggy-back versus conventional technique in liver transplantation: report of a randomized trial. Transpl Int 1997; 10:109-112. (Pubitemid 27110499)
15. Miyamoto S, Polak WG, Geuken E, et al. Liver transplantation with preservation of the inferior vena cava. A comparison of conventional and piggyback techniques in adults. Clin Transplant 2004; 18:686-693.
16. Kang Y, Audu P. Coagulation and liver transplantation. Anesthesiol Clin 2006; 44:17-36.
17. Kang Y, Lewis JH, Navalgund A, et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987; 66:766-773. (Pubitemid 17088976)
18. Porte RJ, Bontempo FA, Knot EA, et al. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989; 47:978-984.
19. Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996; 85:1043-1048. (Pubitemid 26378289)
20. Dalmau A, Sabate A, Acosta F, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000; 91:29-34. (Pubitemid 30437053)
21. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALY study group. Lancet 2000; 355:1303-1309. (Pubitemid 30199001)
22. Findlay JY, Rettke SR, Ereth MH, et al. Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. Liver Transpl 2001; 7:802-807.
23. Prah GN, Lisman S, Maslow AD, et al. Transesophageal echocardiography reveals an unusual cause of hemodynamic collapses during orthotopic liver transplantation-two case reports. Transplantation 1995; 59:921-925.
24. Manji M, Isaac JL, Bion J. Survival from massive intraoperative pulmonary thromboembolism during orthotopic liver transplantation. Br J Anesth 1998; 80:685-687. (Pubitemid 28224936)
25. Sopher M, Braunfeld M, Shackleton C, et al. Fatal embolism during liver transplantation. Anesthesiology 1997; 87:429-432.
26. O'Connor CJ, Roozeboom D, Brown R, Tuman KJ. Pulmonary thromboembolism during liver transplantation: possible association with antifibrinolytic drugs and novel treatment options. Anesth Analg 2000; 91:296-299. (Pubitemid 30624284)
27. Gologorsky E, De Wolf AM, Scott V, et al. Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transpl 2007; 7:783-789.
28. Ramsay MAE, Randall HB, Burton E. Intravascular thrombosis and thromboembolism during liver transplantation: antifibrinolytic therapy implicated. Liver Transpl 2004; 10:310-314. (Pubitemid 38240132)
29. Ellenberger C, Mentha G, Giostra E, Licker M. Cardiovascular collapse due to massive pulmonary thromboembolism during orthotopic liver transplantation. J Clin Anesth 2006; 18:367-371. (Pubitemid 44176356)
30. Molenaar IQ, Warnaar N, Groen H, et al. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review. Am J Transplant 2007; 7:185-194. (Pubitemid 44952872)
31. McCluskey SA, Karkouti K, Wijeysundera DN, et al. Derivation of a risk index for the prediction of massive blood transfusion in liver transplantation. Liver Transpl 2006; 12:1584-1593. (Pubitemid 44742537)
32. Li M, Zhang L, Yang L. Fluids administration and coagulation characteristics in patients with different model for end-stage liver disease scores undergoing orthotopic liver transplantation. Chin Med J 2007; 120:1963-1968. (Pubitemid 350237800)
33. Olenchock SA, Lee PH, Yehoshua T, et al. Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3337 patients. Ann Thorac Surg 2008; 86:560-566. (Pubitemid 351978046)
34. Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319-2331.
35. Kertai MD, Vargas KS, Royston D, et al. Aprotinin and perioperative complications in cardiac surgery. J Cardiovasc Surg 2007; 48:761-772. (Pubitemid 350268022)
36. Lindvall G, Sartipy U, Ivert T, et al. Aprotinin is not associated with postoperative renal impairment after primary coronary surgery. Ann Thorac Surg 2008; 86:13-19.
37. Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358:840-842. (Pubitemid 351284456)
38. Balduini CL, Noris P, Balletti S, et al. In vitro and in vivo effects of desmopressin on platelet function. Haematologica 1999; 84:891-896.
39. Kang Y, Scott V, De Wolf A, et al. In vitro effects of DDAVP during liver transplantation. Transplant Proc 1993; 25:1821-1822.
40. Mor E, Jennings L, Gonwa TA, et al. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obstet 1993; 176:219-227. (Pubitemid 23073566)
41. Cacciarelli TV, Keeffe EB, Moore DH, et al. Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation. Arch Surg 1999; 134:25-29.
42. Ramos E, Dalmau A, Sabate A, et al. Intraoperative red blood cell transfusion in liver transplantation: influence on patient outcome, prediction of requirements, and measures to reduce them. Liver Transpl 2003; 9:1320-1327. (Pubitemid 37540380)
43. Cadwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44:1039-1046. (Pubitemid 46489567)
44. Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007; 24:250-258. (Pubitemid 47174040)
45. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44:53-61. (Pubitemid 44049138)
46. Pereboom ITA, Lisman T, Porte RJ. Platelets in liver transplantation: friend or foe? Liver Transpl 2008; 14:923-931. This paper is an interesting review of the role of platelets in patients with end-stage liver disease undergoing OLT.
47. Tripodi A, Primignanai M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44:440-445. (Pubitemid 44214883)
48. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their significance and need for clinical and laboratory research. J Hepatol 2007; 56:727-733. This paper is a very interesting review of the hemostatic problems of patients with end-stage liver disease. (Pubitemid 46400157)
49. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106:1366-1375.
50. Lang T, von Depka M. Possibilities and limitations of thromboleastometry/thromboelastography. Hämostaseologie 2006; 26 (Suppl 1):S21-S39.
51. Farriols Danes A, Gallur Cuenca L, Rodriguez Bueno S, et al. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sanguinis 2008; 94:221-226.
52. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2006; 5:266-273. (Pubitemid 46139450)
53. Planinsic RM, Van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005; 8:895-900. (Pubitemid 41122446)
54. Lodge JPA, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 8:973-979. (Pubitemid 41122456)